Buscar
Mostrando ítems 1-6 de 6
Dialysis prescription in acute kidney injury: when and how much?
(Springer, 2020)
Acute kidney injury (AKI) constitutes a serious public health problem because of its very high cost and mortality rate, with
an increasing incidence, phenomenon which is explained by the increasingly number of older patients suffering from several
comorbidities admitted in the intensive care units. Despite the new AKI definition and classification, the use of novel AKI
biomarkers and modern technologies, as an attempt to achieve an early AKI detection and treatment, and consequently to
better clinical outcomes, AKI mortality particularly in ...
Kidney-gut crosstalk in renal disease
(Springer Nature, 2020)
Introduction The colon has an important role in managing nitrogenous waste products, electrolytes, and mineral balance during
kidney diseases. However, colonic microbiota produces uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, in chronic
kidney disease (CKD) patients, which due to their proinflammatory properties contribute to CKD progression. Conversely, in
acute renal injury patients, intestinal microbiota could reduce inflammation by secreting short-chain fatty acids and inducing a
renal protective immune response. However, ...
Primary prevention for acute kidney injury in ambulatory patients
(Taylor & Francis, 2020)
Acute kidney injury (AKI) is a heterogeneous group of conditions characterized by a sudden decrease in glomerular filtration rate (GFR), which usually induces the accumulation of nitrogenous-waste substances in the blood. It is expressed as an increase in serum creatinine levels (≥ 0.3 mg/dl within 48 hours or ≥1.5 times from baseline within the previous 7 days) or by a urine volume reduction of ˂0.5 ml/kg/h in 6 hours [1]. AKI is a relevant condition since it is usually associated with 1–7% and 30–50% of hospital and intensive care unit (ICU) ...
Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications
(Springer, 2020)
Type 2 diabetes mellitus (DM2) is a chronic condition that affects more than 400 million individuals worldwide. In DM2 patients, an appropriate glycemic control slows the onset and delays the progression of all its micro and macrovascular complications. Even though there are several glucose-lowering drugs, only approximately half of patients achieve glycemic control, while undesirable adverse effects (e.g., low serum glucose) normally affect treatment. Therefore, there is a need for
new types of treatments. Sodium-glucose cotransporter 2 inhibitors ...
Medicina biosemiótica: de una medicina de efectos a una medicina de procesos
(Sociedad Argentina de Pediatría, 2020)
La medicina contemporánea se caracteriza por
una creciente subespecialización, así como por la
adquisición de un mayor conocimiento respecto
de la interacción entre las distintas estructuras
del organismo (biosemiótica) tanto en estado
de salud como de enfermedad. Se propone,
en este artículo, una nueva conceptualización
del organismo basada en la perspectiva de
considerarlo conformado por un espacio
biológico (células, tejidos y órganos) y un
espacio biosemiótico (intercambio de señales
entre ellos). Su desarrollo daría lugar a ...
Optimizing dialysis dose in the context of frailty: an exploratory study
(Springer Nature, 2020)
Introduction Frailty is a multicausal syndrome characterized by a decrease in strength, resistance and physiological function,
which makes the individual vulnerable and dependent, and increases his/her mortality. This syndrome is more prevalent
among older individuals, and chronic kidney disease patients, particularly those on dialysis. Dialysis dose is currently
standardized for hemodialysis (HD) patients regardless of their age and functional status. However, it has been postulated
that the dialysis dose required in older patients, especially ...